0 CHECKOUT

Measles - Pipeline Review, H1 2015

  • ID: 3196293
  • March 2015
  • 59 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline plc
  • Prometheon Pharma, LLC
  • Vical Incorporated
  • MORE

Measles - Pipeline Review, H1 2015

Summary

This, ‘Measles - Pipeline Review, H1 2015’, provides an overview of the Measles’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Measles, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Measles and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline plc
  • Prometheon Pharma, LLC
  • Vical Incorporated
  • MORE

List of Tables:

List of Figures:

Introduction

REPORT COVERAGE

Measles Overview

Therapeutics Development

Pipeline Products for Measles - Overview

Pipeline Products for Measles - Comparative Analysis

Measles - Therapeutics under Development by Companies

Measles - Therapeutics under Investigation by Universities/Institutes

Measles - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Measles - Products under Development by Companies

Measles - Products under Investigation by Universities/Institutes

Measles - Companies Involved in Therapeutics Development

Beijing Tiantan Biological Products Co., Ltd.

Biological E. Limited

China National Pharmaceutical Group Corporation

GlaxoSmithKline plc

Prometheon Pharma, LLC

Serum Institute of India Limited

Universal Stabilization Technologies, Inc.

Vical Incorporated

Zydus Cadila Healthcare Limited

Measles - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(measles [schwarz strain] + mumps [RIT 4385 strain] + rubella [wistar RA 27/3 strain])vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AS-136A - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for Measles, Mumps and Rubella - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ERDRP-0519 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + mumps + rubella + varicella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + mumps + rubella + varicella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + mumps + rubella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + mumps + rubella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + rubella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + rubella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles + rubella vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles [edmonston - zagreb strain] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

measles vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Measles - Recent Pipeline Updates

Measles - Dormant Projects

Measles - Product Development Milestones

Featured News & Press Releases

Nov 24, 2014: Powdered Measles Vaccine Found Safe In Early Clinical Trials

Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Measles, H1 2015

Number of Products under Development for Measles - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Late Stage Development, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Comparative Analysis by Unknown Stage Development, H1 2015

Products under Development by Companies, H1 2015

Products under Investigation by Universities/Institutes, H1 2015

Measles - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015

Measles - Pipeline by Biological E. Limited, H1 2015

Measles - Pipeline by China National Pharmaceutical Group Corporation, H1 2015

Measles - Pipeline by GlaxoSmithKline plc, H1 2015

Measles - Pipeline by Prometheon Pharma, LLC, H1 2015

Measles - Pipeline by Serum Institute of India Limited, H1 2015

Measles - Pipeline by Universal Stabilization Technologies, Inc., H1 2015

Measles - Pipeline by Vical Incorporated, H1 2015

Measles - Pipeline by Zydus Cadila Healthcare Limited, H1 2015

Assessment by Monotherapy Products, H1 2015

Assessment by Combination Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Measles Therapeutics - Recent Pipeline Updates, H1 2015

Measles - Dormant Projects, H1 2015

List of Figures:

Number of Products under Development for Measles, H1 2015

Number of Products under Development for Measles - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Number of Products under Investigation by Universities/Institutes, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Products, H1 2015

Assessment by Monotherapy Products, H1 2015

Assessment by Combination Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Beijing Tiantan Biological Products Co., Ltd.
- Biological E. Limited
- China National Pharmaceutical Group Corporation
- GlaxoSmithKline plc
- Prometheon Pharma, LLC
- Serum Institute of India Limited
- Universal Stabilization Technologies, Inc.
- Vical Incorporated
- Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.